APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psychoactive Substances

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Psychoactive Substances Market Analysis and Forecast 2026-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchPsychoactive Substances Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Psychoactive Substances Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Psychoactive Substances Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psychoactive Substances Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Psychoactive Substances Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Psychoactive Substances market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Psychoactive Substances is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Psychoactive Substances is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Psychoactive Substances is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Psychoactive Substances is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Psychoactive Substances include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Psychoactive Substances, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Psychoactive Substances, also provides the revenue of main regions and countries. Of the upcoming market potential for Psychoactive Substances, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Psychoactive Substances revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Psychoactive Substances market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Psychoactive Substances revenue, projected growth trends, production technology, application and end-user industry.

Psychoactive Substances Segment by Company

Alpha-CAT

AusCann Group Holdings Pty Ltd.

Cannabics Pharmaceuticals Inc.

Cape Bouvard Technologies Pty Ltd

Cyrelian Pty Ltd.

Enecta.

GD Pharma

GW Pharmaceuticals PLC.

MedReleaf Australia

Teewinot Life Sciences

Tilray

Zynerba Pharmaceuticals

Psychoactive Substances Segment by Type

Cannabinoids

Hallucinogens

Stimulants

Depressants

Psychoactive Substances Segment by Application

Neuropathic Disorders

Spasticity

Cancer

Psychoactive Substances Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Psychoactive Substances in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Psychoactive Substances company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychoactive Substances revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Psychoactive Substances Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cannabinoids Major Player Table 3. Hallucinogens Major Player Table 4. Stimulants Major Player Table 5. Depressants Major Player Table 6. Global Psychoactive Substances Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Neuropathic Disorders Major Player Table 8. Spasticity Major Player Table 9. Cancer Major Player Table 10. Psychoactive Substances Industry Trends Table 11. Psychoactive Substances Industry Drivers Table 12. Psychoactive Substances Industry Opportunities and Challenges Table 13. Psychoactive Substances Industry Restraints Table 14. Global Psychoactive Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Psychoactive Substances Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Psychoactive Substances Market Share by Region (2021-2026) Table 17. Global Psychoactive Substances Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Psychoactive Substances Market Share by Region (2027-2032) Table 19. Global Psychoactive Substances Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Psychoactive Substances Revenue Market Share by Players (2021-2026) Table 21. Global Psychoactive Substances Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Psychoactive Substances Key Players Headquarters & Area Served Table 23. Global Psychoactive Substances Players, Product Type & Application Table 24. Global Psychoactive Substances Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Psychoactive Substances by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Psychoactive Substances Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Psychoactive Substances Revenue Market Share by Type (2021-2026) Table 31. Global Psychoactive Substances Revenue Market Share by Type (2027-2032) Table 32. Global Psychoactive Substances Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Psychoactive Substances Revenue Market Share by Application (2021-2026) Table 36. Global Psychoactive Substances Revenue Market Share by Application (2027-2032) Table 37. Alpha-CAT Company Information Table 38. Alpha-CAT Business Overview Table 39. Alpha-CAT Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Alpha-CAT Psychoactive Substances Product Portfolio Table 41. Alpha-CAT Recent Development Table 42. AusCann Group Holdings Pty Ltd. Company Information Table 43. AusCann Group Holdings Pty Ltd. Business Overview Table 44. AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio Table 46. AusCann Group Holdings Pty Ltd. Recent Development Table 47. Cannabics Pharmaceuticals Inc. Company Information Table 48. Cannabics Pharmaceuticals Inc. Business Overview Table 49. Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio Table 51. Cannabics Pharmaceuticals Inc. Recent Development Table 52. Cape Bouvard Technologies Pty Ltd Company Information Table 53. Cape Bouvard Technologies Pty Ltd Business Overview Table 54. Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio Table 56. Cape Bouvard Technologies Pty Ltd Recent Development Table 57. Cyrelian Pty Ltd. Company Information Table 58. Cyrelian Pty Ltd. Business Overview Table 59. Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio Table 61. Cyrelian Pty Ltd. Recent Development Table 62. Enecta. Company Information Table 63. Enecta. Business Overview Table 64. Enecta. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Enecta. Psychoactive Substances Product Portfolio Table 66. Enecta. Recent Development Table 67. GD Pharma Company Information Table 68. GD Pharma Business Overview Table 69. GD Pharma Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. GD Pharma Psychoactive Substances Product Portfolio Table 71. GD Pharma Recent Development Table 72. GW Pharmaceuticals PLC. Company Information Table 73. GW Pharmaceuticals PLC. Business Overview Table 74. GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio Table 76. GW Pharmaceuticals PLC. Recent Development Table 77. MedReleaf Australia Company Information Table 78. MedReleaf Australia Business Overview Table 79. MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. MedReleaf Australia Psychoactive Substances Product Portfolio Table 81. MedReleaf Australia Recent Development Table 82. Teewinot Life Sciences Company Information Table 83. Teewinot Life Sciences Business Overview Table 84. Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Teewinot Life Sciences Psychoactive Substances Product Portfolio Table 86. Teewinot Life Sciences Recent Development Table 87. Tilray Company Information Table 88. Tilray Business Overview Table 89. Tilray Psychoactive Substances Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Tilray Psychoactive Substances Product Portfolio Table 91. Tilray Recent Development Table 92. Zynerba Pharmaceuticals Company Information Table 93. Zynerba Pharmaceuticals Business Overview Table 94. Zynerba Pharmaceuticals Psychoactive Substances Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio Table 96. Zynerba Pharmaceuticals Recent Development Table 97. North America Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Psychoactive Substances Revenue by Country (2021-2026) & (US$ Million) Table 103. North America Psychoactive Substances Revenue by Country (US$ Million) & (2027-2032) Table 104. Europe Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Psychoactive Substances Revenue by Country (2021-2026) & (US$ Million) Table 110. Europe Psychoactive Substances Revenue by Country (US$ Million) & (2027-2032) Table 111. China Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 112. China Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 113. China Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 114. China Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 116. Asia Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 117. Asia Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 118. Asia Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Psychoactive Substances Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Psychoactive Substances Revenue by Region (US$ Million) & (2021-2026) Table 121. Asia Psychoactive Substances Revenue by Region (US$ Million) & (2027-2032) Table 122. SAMEA Psychoactive Substances Revenue by Type (2021-2026) & (US$ Million) Table 123. SAMEA Psychoactive Substances Revenue by Type (2027-2032) & (US$ Million) Table 124. SAMEA Psychoactive Substances Revenue by Application (2021-2026) & (US$ Million) Table 125. SAMEA Psychoactive Substances Revenue by Application (2027-2032) & (US$ Million) Table 126. SAMEA Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. SAMEA Psychoactive Substances Revenue by Country (2021-2026) & (US$ Million) Table 128. SAMEA Psychoactive Substances Revenue by Country (US$ Million) & (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Psychoactive Substances Image Figure 2. Global Psychoactive Substances Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psychoactive Substances Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cannabinoids Image Figure 5. Hallucinogens Image Figure 6. Stimulants Image Figure 7. Depressants Image Figure 8. Global Psychoactive Substances Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Psychoactive Substances Market Size Share 2021 VS 2025 VS 2032 Figure 10. Neuropathic Disorders Image Figure 11. Spasticity Image Figure 12. Cancer Image Figure 13. Global Psychoactive Substances Market Size (US$ Million) & (2021-2032) Figure 14. Global Psychoactive Substances Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Psychoactive Substances Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Psychoactive Substances Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Psychoactive Substances Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Psychoactive Substances Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Psychoactive Substances Revenue Market Share by Type (2021-2032) Figure 21. Global Psychoactive Substances Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Psychoactive Substances Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Psychoactive Substances Revenue Market Share by Application (2021-2032) Figure 24. North America Psychoactive Substances Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Psychoactive Substances Revenue Share by Type (2021-2032) Figure 26. North America Psychoactive Substances Revenue Share by Application (2021-2032) Figure 27. North America Psychoactive Substances Revenue Share by Country (2021-2032) Figure 28. United States Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Psychoactive Substances Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Psychoactive Substances Revenue Share by Type (2021-2032) Figure 33. Europe Psychoactive Substances Revenue Share by Application (2021-2032) Figure 34. Europe Psychoactive Substances Revenue Share by Country (2021-2032) Figure 35. Germany Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Psychoactive Substances Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Psychoactive Substances Revenue Share by Type (2021-2032) Figure 45. China Psychoactive Substances Revenue Share by Application (2021-2032) Figure 46. Asia Psychoactive Substances Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Psychoactive Substances Revenue Share by Type (2021-2032) Figure 48. Asia Psychoactive Substances Revenue Share by Application (2021-2032) Figure 49. Asia Psychoactive Substances Revenue Share by Region (2021-2032) Figure 50. Japan Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Psychoactive Substances Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Psychoactive Substances Revenue Share by Type (2021-2032) Figure 58. SAMEA Psychoactive Substances Revenue Share by Application (2021-2032) Figure 59. SAMEA Psychoactive Substances Revenue Share by Country (2021-2032) Figure 60. Brazil Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Psychoactive Substances Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cannabinoids
  • Hallucinogens
  • Stimulants
  • Depressants
Applications
  • Neuropathic Disorders
  • Spasticity
  • Cancer
Companies covered
  • Alpha-CAT
  • AusCann Group Holdings Pty Ltd.
  • Cannabics Pharmaceuticals Inc.
  • Cape Bouvard Technologies Pty Ltd
  • Cyrelian Pty Ltd.
  • Enecta.
  • GD Pharma
  • GW Pharmaceuticals PLC.
  • MedReleaf Australia
  • Teewinot Life Sciences
  • Tilray
  • Zynerba Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Psychoactive Substances Market by Type
  3. 1.2.1 Global Psychoactive Substances Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cannabinoids
  5. 1.2.3 Hallucinogens
  6. 1.2.4 Stimulants
  7. 1.2.5 Depressants
  8. 1.3 Psychoactive Substances Market by Application
  9. 1.3.1 Global Psychoactive Substances Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Neuropathic Disorders
  11. 1.3.3 Spasticity
  12. 1.3.4 Cancer
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Psychoactive Substances Market Dynamics
  1. 2.1 Psychoactive Substances Industry Trends
  2. 2.2 Psychoactive Substances Industry Drivers
  3. 2.3 Psychoactive Substances Industry Opportunities and Challenges
  4. 2.4 Psychoactive Substances Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Psychoactive Substances Market Perspective (2021-2032)
  2. 3.2 Global Psychoactive Substances Growth Trends by Region
  3. 3.2.1 Global Psychoactive Substances Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Psychoactive Substances Market Size by Region (2021-2026)
  5. 3.2.3 Global Psychoactive Substances Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Psychoactive Substances Revenue by Players
  2. 4.1.1 Global Psychoactive Substances Revenue by Players (2021-2026)
  3. 4.1.2 Global Psychoactive Substances Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Psychoactive Substances Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Psychoactive Substances Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Psychoactive Substances Key Players Headquarters & Area Served
  7. 4.4 Global Psychoactive Substances Players, Product Type & Application
  8. 4.5 Global Psychoactive Substances Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Psychoactive Substances Market CR5 and HHI
  11. 4.6.3 2025 Psychoactive Substances Tier 1, Tier 2, and Tier 3
5 Psychoactive Substances Market Size by Type
  1. 5.1 Global Psychoactive Substances Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Psychoactive Substances Revenue by Type (2021-2032)
  3. 5.3 Global Psychoactive Substances Revenue Market Share by Type (2021-2032)
6 Psychoactive Substances Market Size by Application
  1. 6.1 Global Psychoactive Substances Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Psychoactive Substances Revenue by Application (2021-2032)
  3. 6.3 Global Psychoactive Substances Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alpha-CAT
  2. 7.1.1 Alpha-CAT Company Information
  3. 7.1.2 Alpha-CAT Business Overview
  4. 7.1.3 Alpha-CAT Psychoactive Substances Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alpha-CAT Psychoactive Substances Product Portfolio
  6. 7.1.5 Alpha-CAT Recent Developments
  7. 7.2 AusCann Group Holdings Pty Ltd.
  8. 7.2.1 AusCann Group Holdings Pty Ltd. Company Information
  9. 7.2.2 AusCann Group Holdings Pty Ltd. Business Overview
  10. 7.2.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
  12. 7.2.5 AusCann Group Holdings Pty Ltd. Recent Developments
  13. 7.3 Cannabics Pharmaceuticals Inc.
  14. 7.3.1 Cannabics Pharmaceuticals Inc. Company Information
  15. 7.3.2 Cannabics Pharmaceuticals Inc. Business Overview
  16. 7.3.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
  18. 7.3.5 Cannabics Pharmaceuticals Inc. Recent Developments
  19. 7.4 Cape Bouvard Technologies Pty Ltd
  20. 7.4.1 Cape Bouvard Technologies Pty Ltd Company Information
  21. 7.4.2 Cape Bouvard Technologies Pty Ltd Business Overview
  22. 7.4.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
  24. 7.4.5 Cape Bouvard Technologies Pty Ltd Recent Developments
  25. 7.5 Cyrelian Pty Ltd.
  26. 7.5.1 Cyrelian Pty Ltd. Company Information
  27. 7.5.2 Cyrelian Pty Ltd. Business Overview
  28. 7.5.3 Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
  30. 7.5.5 Cyrelian Pty Ltd. Recent Developments
  31. 7.6 Enecta.
  32. 7.6.1 Enecta. Company Information
  33. 7.6.2 Enecta. Business Overview
  34. 7.6.3 Enecta. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Enecta. Psychoactive Substances Product Portfolio
  36. 7.6.5 Enecta. Recent Developments
  37. 7.7 GD Pharma
  38. 7.7.1 GD Pharma Company Information
  39. 7.7.2 GD Pharma Business Overview
  40. 7.7.3 GD Pharma Psychoactive Substances Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GD Pharma Psychoactive Substances Product Portfolio
  42. 7.7.5 GD Pharma Recent Developments
  43. 7.8 GW Pharmaceuticals PLC.
  44. 7.8.1 GW Pharmaceuticals PLC. Company Information
  45. 7.8.2 GW Pharmaceuticals PLC. Business Overview
  46. 7.8.3 GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
  48. 7.8.5 GW Pharmaceuticals PLC. Recent Developments
  49. 7.9 MedReleaf Australia
  50. 7.9.1 MedReleaf Australia Company Information
  51. 7.9.2 MedReleaf Australia Business Overview
  52. 7.9.3 MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (2021-2026)
  53. 7.9.4 MedReleaf Australia Psychoactive Substances Product Portfolio
  54. 7.9.5 MedReleaf Australia Recent Developments
  55. 7.10 Teewinot Life Sciences
  56. 7.10.1 Teewinot Life Sciences Company Information
  57. 7.10.2 Teewinot Life Sciences Business Overview
  58. 7.10.3 Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teewinot Life Sciences Psychoactive Substances Product Portfolio
  60. 7.10.5 Teewinot Life Sciences Recent Developments
  61. 7.11 Tilray
  62. 7.11.1 Tilray Company Information
  63. 7.11.2 Tilray Business Overview
  64. 7.11.3 Tilray Psychoactive Substances Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Tilray Psychoactive Substances Product Portfolio
  66. 7.11.5 Tilray Recent Developments
  67. 7.12 Zynerba Pharmaceuticals
  68. 7.12.1 Zynerba Pharmaceuticals Company Information
  69. 7.12.2 Zynerba Pharmaceuticals Business Overview
  70. 7.12.3 Zynerba Pharmaceuticals Psychoactive Substances Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
  72. 7.12.5 Zynerba Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Psychoactive Substances Revenue (2021-2032)
  2. 8.2 North America Psychoactive Substances Revenue by Type (2021-2032)
  3. 8.2.1 North America Psychoactive Substances Revenue by Type (2021-2026)
  4. 8.2.2 North America Psychoactive Substances Revenue by Type (2027-2032)
  5. 8.3 North America Psychoactive Substances Revenue Share by Type (2021-2032)
  6. 8.4 North America Psychoactive Substances Revenue by Application (2021-2032)
  7. 8.4.1 North America Psychoactive Substances Revenue by Application (2021-2026)
  8. 8.4.2 North America Psychoactive Substances Revenue by Application (2027-2032)
  9. 8.5 North America Psychoactive Substances Revenue Share by Application (2021-2032)
  10. 8.6 North America Psychoactive Substances Revenue by Country
  11. 8.6.1 North America Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Psychoactive Substances Revenue by Country (2021-2026)
  13. 8.6.3 North America Psychoactive Substances Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Psychoactive Substances Revenue (2021-2032)
  2. 9.2 Europe Psychoactive Substances Revenue by Type (2021-2032)
  3. 9.2.1 Europe Psychoactive Substances Revenue by Type (2021-2026)
  4. 9.2.2 Europe Psychoactive Substances Revenue by Type (2027-2032)
  5. 9.3 Europe Psychoactive Substances Revenue Share by Type (2021-2032)
  6. 9.4 Europe Psychoactive Substances Revenue by Application (2021-2032)
  7. 9.4.1 Europe Psychoactive Substances Revenue by Application (2021-2026)
  8. 9.4.2 Europe Psychoactive Substances Revenue by Application (2027-2032)
  9. 9.5 Europe Psychoactive Substances Revenue Share by Application (2021-2032)
  10. 9.6 Europe Psychoactive Substances Revenue by Country
  11. 9.6.1 Europe Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Psychoactive Substances Revenue by Country (2021-2026)
  13. 9.6.3 Europe Psychoactive Substances Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Psychoactive Substances Revenue (2021-2032)
  2. 10.2 China Psychoactive Substances Revenue by Type (2021-2032)
  3. 10.2.1 China Psychoactive Substances Revenue by Type (2021-2026)
  4. 10.2.2 China Psychoactive Substances Revenue by Type (2027-2032)
  5. 10.3 China Psychoactive Substances Revenue Share by Type (2021-2032)
  6. 10.4 China Psychoactive Substances Revenue by Application (2021-2032)
  7. 10.4.1 China Psychoactive Substances Revenue by Application (2021-2026)
  8. 10.4.2 China Psychoactive Substances Revenue by Application (2027-2032)
  9. 10.5 China Psychoactive Substances Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Psychoactive Substances Revenue (2021-2032)
  2. 11.2 Asia Psychoactive Substances Revenue by Type (2021-2032)
  3. 11.2.1 Asia Psychoactive Substances Revenue by Type (2021-2026)
  4. 11.2.2 Asia Psychoactive Substances Revenue by Type (2027-2032)
  5. 11.3 Asia Psychoactive Substances Revenue Share by Type (2021-2032)
  6. 11.4 Asia Psychoactive Substances Revenue by Application (2021-2032)
  7. 11.4.1 Asia Psychoactive Substances Revenue by Application (2021-2026)
  8. 11.4.2 Asia Psychoactive Substances Revenue by Application (2027-2032)
  9. 11.5 Asia Psychoactive Substances Revenue Share by Application (2021-2032)
  10. 11.6 Asia Psychoactive Substances Revenue by Country
  11. 11.6.1 Asia Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Psychoactive Substances Revenue by Country (2021-2026)
  13. 11.6.3 Asia Psychoactive Substances Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Psychoactive Substances Revenue (2021-2032)
  2. 12.2 SAMEA Psychoactive Substances Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Psychoactive Substances Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Psychoactive Substances Revenue by Type (2027-2032)
  5. 12.3 SAMEA Psychoactive Substances Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Psychoactive Substances Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Psychoactive Substances Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Psychoactive Substances Revenue by Application (2027-2032)
  9. 12.5 SAMEA Psychoactive Substances Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Psychoactive Substances Revenue by Country
  11. 12.6.1 SAMEA Psychoactive Substances Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Psychoactive Substances Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Psychoactive Substances Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst